Compare Quest Diagnostics Inc (DGX) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs InMode Ltd — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while InMode Ltd trades at $14.21 (market cap $809.93M). The key difference: Quest Diagnostics Inc is far larger — about 31.5× InMode Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and InMode Ltd for 28 Days on average.
| DGX | INMD | |
|---|---|---|
Market Cap | $25.48B | $809.93M |
Volume | 941,866 | 365,490 |
Sector | Health | Health |
52-Week High | $247.45 | $16.62 |
52-Week Low | $173.49 | $12.76 |
Typical Hold Time | 56 Days | 28 Days |
Enterprise Value | $31.23B | $313.27M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
InMode (INMD) trades at $14.21, up 1.43% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent profitability. Recent Q2 2026 earnings beat expectations with $95.6M revenue, while facing shareholder activism from Steel Partners' $16.75 per share acquisition offer.
Investment outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical industry softness. Key opportunities include international growth and new product launches like Morpheus8 Cool, while risks involve US sales declines and capital allocation concerns. The stock presents value characteristics but requires monitoring of management's strategic response to acquisition pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
